Recommended

FDA tightens COVID vaccine use
Decentralised manufacturing consortium launched
Trial boost for myasthenia gravis drug
FDA starts publishing daily AE data
WEBINAR | The Future of Sterility Testing: One-Day Results with Advanced RT-rt PCR Technology | 5 NOV
WEBINAR | Mastering Impurity Profiling: USP’s Evolving Standards and Strategies | 15 OCT
news

CAR T therapy exhibits encouraging proficiency in R/R LBCL

1
SHARES

The first study assessing Yescarta® as second-line therapy for transplant ineligible relapsed/refractory (R/R) large B-cell lymphoma (LBCL) demonstrated durable remission rate in a Phase II trial.

CAR T therapy Yescarta exhibits encouraging proficiency in R/R LBCL

Kite’s Yescarta® (axicabtagene ciloleucel) facilitated a high response rate in transplant ineligible relapsed/refractory (R/R) large B-cell lymphoma (LBCL), Phase II study results show.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

Patients with R/R LBCL who had received one prior line of therapy and were deemed ineligible for high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) were evaluated in the trial.

Phase II “ALYCANTE is the first study to assess axicabtagene ciloleucel as second-line therapy for transplant ineligible R/R LBCL and the results showed high response rates and durable remission in this hard-to-treat population,” stated Professor Roch Houot, coordinator of the ALYCANTE study and Head of the Haematology Department at University Hospital of Rennes in France.

Results from the Phase II Yescarta trial

The study achieved a best objective response (OR) and complete response (CR) rates of 91.9 percent and 82.3 percent, respectively.

Complete metabolic response (CMR) of 71 percent was observed at three months versus 12 percent expected with standard of care. At six months, 59.7 percent of patients remained in CMR. Kite highlighted that CMR are negative findings on a PET study during or after antitumor therapy.

Median progression-free survival (PFS) from infusion, after a median follow-up of 12 months, was 11.8 months. Consequently, 48.8 percent of evaluated patients were alive and progression-free at 12 months.

For [R/R LBCL] patients deemed ineligible for stem cell transplant, the ALYCANTE data demonstrate that Yescarta can provide another option for a potential curative therapy”

“Transplant ineligible patients with aggressive relapsed or refractory B-cell lymphomas face poor prognosis,” added Professor Houot.

In clinical practice, about half of patients with R/R LBCL are considered ineligible for HDCT/ASCT, Kite stated. “For patients who are deemed ineligible for stem cell transplant, the ALYCANTE data demonstrate that Yescarta can provide another option for a potential curative therapy,” shared Kite’s Global Head of Clinical Development, Dr Frank Neumann, PhD, SVP.

Full findings from the CAR T-cell therapy study were published in Nature Medicine.

The Yescarta study was funded by Kite, a Gilead Company, and carried out with axicabtagene ciloleucel CAR T-cell therapy manufactured by Kite.

Kite releases pivotal CAR T therapy Phase III study results

Share via
Share via